granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

, e.g., supermarket, food and restaurants (only for takeaway), drug stores.  Online sales continued to grow remarkably by 150.0% YoY.  Gross profit margin from sale of goods improved outstandingly to

of;- BAFS - Long-term loans from TMB was of Bt2,250.0 million due on April 30, 2026 with 3 years grace period and quarterly, principal repayment: Bt80.4 million/period (the last repayment will be made

, increasing by Bt3,646.3 million from December 31, 2017 or 137.8%. These comprise of;- BAFS - Long-term loans from TMB was of Bt2,089.3 million due on April 30, 2026 with 3 years grace period and quarterly

loans from banks were Bt6,292.3 million, increasing by Bt3,646.3 million from December 31, 2017 or 137.8%. These comprise of;- BAFS - Long-term loans from TMB was of Bt2,089.3 million due on April 30

, 2018 or 7.0%. These comprise of;- BAFS - Long-term loans from TMB was of Bt2,008.9 million due on April 30, 2026 with 3 years grace period and quarterly, principal repayment: Bt80.4 million/period (the

CORPORATION INVESTMENT ADVISORY SECURITIES , COMPANY LIMITED TRINITY SECURITIES COMPANY LIMITED TMB ASSET MANAGEMENT COMPANY LIMITED TALIS ASSET MANAGEMENT COMPANY LIMITED TISCO SECURITIES COMPANY LIMITED TISCO

baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company

30, 2019 which was quarterly, principal repayment at rate of MLR minus percent of fixed rate per annum - Long-term loans from TMB was of Bt2,250.0 million due on April 30, 2026 with 3 years grace